Trinity Biotech (TRIB) Downgraded by ValuEngine to Strong Sell


Separately, Zacks Investment Research downgraded Trinity Biotech from a "hold" rating to a "sell" rating in a research report on Friday, April 13th. NASDAQ TRIB opened at $5.00 on Friday.



from Biotech News